EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the MYCN interaction network in neuroblastoma

Chelsea Xinyi Yow, Sharon Yeoh iD, Eoin Leen, Richard Bayliss iD

Bioscience Reports · 17.06.2026 · 46 (6)

DOI: 10.1042/bsr20250104 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioscience Reports, online erschienen am 15.06.2026. Verfasst von Chelsea Xinyi Yow und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, LS2 9JT, U.K. Hauptthemen laut MEDLINE: Neuroblastoma, N-Myc Proto-Oncogene Protein, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI | Medical Research Council (MRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroblastoma is a common solid tumour in children and accounts for a disproportionate share of childhood cancer mortality. High-risk neuroblastoma is a major clinical challenge, with survival rates below 50% despite intensive therapy. Amplification of the MYCN oncogene is a hallmark of high-risk disease. MYCN protein is a transcription factor that promotes proliferation and blocks differentiation. MYCN is often described as ‘undruggable’ due to its lack of enzymatic activity and intrinsically disordered nature that means it lacks well-defined binding pockets for small molecules. This review explores the molecular interactome of MYCN as an opportunity for therapeutic discovery. We highlight functional and structural features of the interactions with key partners, such as MAX, WDR5, TFIIIC5 and Aurora kinase A. We discuss emerging strategies to disrupt MYCN interactions and to enable its degradation through disruption of protein stabilisation mechanisms or the use of degraders such as proteolysis targeting chimeras. By integrating knowledge of MYCN biology, molecular structures and chemical biology, these approaches provide promising routes towards targeted therapies for MYCN-driven neuroblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaN-Myc Proto-Oncogene ProteinAntineoplastic AgentsHumansAnimalsMolecular Targeted TherapyAurora Kinase AProteolysisProtein Interaction MapsProtein Binding

Stichwörter der Autor:innen

MYCN amplificationdegradersneuroblastomaprotein-protein interactions

Substanzen

N-Myc Proto-Oncogene ProteinMYCN protein, humanAntineoplastic AgentsAurora Kinase A

Autor:innen und Institutionen

  • School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, LS2 9JT, U.K.
  • Astbury Centre for Structural Molecular Biology, University of Leeds, LS2 9JT, U.K.

ORCID-Profile: Sharon Yeoh, Richard Bayliss

Förderung

  • UKRI | Medical Research Council (MRC)

Zitieren

APA

Yow, C. X., Yeoh, S., Leen, E., & Bayliss, R. (2026). Targeting the MYCN interaction network in neuroblastoma. Bioscience Reports, 46(6). https://doi.org/10.1042/bsr20250104

Vancouver

Yow CX, Yeoh S, Leen E, Bayliss R. Targeting the MYCN interaction network in neuroblastoma. Bioscience Reports. 2026;46(6). doi:10.1042/bsr20250104

BibTeX
@article{Yow2026,
  author = {Yow, Chelsea Xinyi and Yeoh, Sharon and Leen, Eoin and Bayliss, Richard},
  title = {Targeting the MYCN interaction network in neuroblastoma},
  journal = {Bioscience Reports},
  year = {2026},
  volume = {46},
  number = {6},
  doi = {10.1042/bsr20250104}
}
Kostenlos starten →